Figure 2From: Assessment of liver stiffness in patients with HCV and mixed cryoglobulinemia undergoing rituximab treatment Changes of liver stiffness values and CD19+ cell levels at baseline, at three months and at six months after the end of treatment. Liver stiffness values (panel A) and CD19+ levels (panel B) were significantly different from those observed before treatment.Back to article page